Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Salamanca – page 7

445 clinical trials in Salamanca, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Salamanca at a glance
445
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

445 trials in Salamanca

Open in trial search

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Colorectal cancer

Recruiting

Study of Telisotuzumab Adizutecan for Adults with Colorectal Cancer Who Have Positive Circulating Tumor DNA After Treatment but No Visible Cancer on Scans

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Recruiting

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fundacion Geltamo

Mantle cell lymphoma

Recruiting

Study of Acalabrutinib with R-CHOP for Patients with Untreated Mantle Cell Lymphoma in Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Heart failure with reduced ejection fraction

Recruiting

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Omecamtiv mecarbil
  • Sponsor:Cytokinetics Inc.

Chronic myelomonocytic leukaemia+1

Recruiting

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Taiho Oncology Inc.

Hormone-refractory prostate cancer

Recruiting

Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Swiss Group for Clinical Cancer Research

Study on Epcoritamab for Patients with Relapsed or Refractory Large B Cell Lymphoma

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Fundacion Geltamo

Pancreatic carcinoma

Recruiting

Study of sotorasib with chemotherapy combination for adult patients with advanced pancreatic cancer who have KRAS p.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Myelodysplastic syndrome

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Plasma cell myeloma refractory

Recruiting

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Adult T-cell lymphoma/leukaemia refractory

Recruiting

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Salamanca

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on various types of lymphomas and leukemias, including innovative combination therapies for mantle cell lymphoma and chronic myeloid leukemia. Multiple trials are evaluating novel treatment approaches for both newly diagnosed and refractory cases.

  • Blood Cancers
  • Solid Tumors
  • Targeted Therapies

Research includes promising treatments for pancreatic adenocarcinoma and advanced breast cancer.

02 Respiratory Medicine

Investigations into preventing and treating respiratory syncytial virus infections, with particular focus on vaccine development for older adults. Studies aim to understand immune responses and evaluate preventive strategies.

  • Viral Infections
  • Vaccine Development
  • Elderly Care

Clinical trials emphasize protection for vulnerable populations against respiratory infections.

03 Immunology Studies

Research addressing chronic spontaneous urticaria and autoimmune conditions, including innovative treatments for systemic sclerosis. Studies evaluate new therapeutic approaches for inflammatory conditions.

  • Autoimmune Disorders
  • Allergic Conditions
  • Novel Therapeutics

Trials focus on improving patient outcomes through targeted immunological interventions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.